Themis Medicare Announces Financial Results for FY 2025-26, Recommends Dividend of Re. 0.50
Themis Medicare Limited announced key outcomes of its Board of Directors meeting held on May 28, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, along with the report issued by Statutory Auditors M/s Krishaan & Co., Chartered Accountants. Furthermore, the Board recommended a final dividend of Re. 0.50 per equity share, aggregating to Rs. 4,60,50,060 /- for the Financial Year ended March 31, 2026, subject to shareholder approval. The company also appointed M/s R. Nanabhoy & Co., Cost Accountants, as the Cost Auditor for the Financial Year 2026-27.Financial Performance Summary
The company's financial statements provide a detailed look at the performance for the year ended March 31, 2026.For the year ended March 31, 2026, the financial summary details are presented below.
Standalone Financial Results (Amount in INR Lakhs)
| Particulars | Year Ended 31/03/2026 | Year Ended 31/03/2025 |
|---|---|---|
| Total Income | 35,159.71 | 41,018.11 |
| Total Expenses | 36,283.89 | 37,641.75 |
| Profit/(Loss) before exceptional items and tax | (1,124.18) | 3,376.36 |
| Profit/ (Loss) for the Period | (1,418.55) | 2,392.15 |
| Total Comprehensive Income | (1,492.07) | 2,361.25 |
| Basic Earnings per share (EPS) | (1.54) | 2.60 |
Consolidated Financial Results (Amount in INR Lakhs)
| Particulars | Year Ended 31/03/2026 | Year Ended 31/03/2025 |
|---|---|---|
| Total Income | 35,159.71 | 41,018.11 |
| Total Expenses | 36,285.20 | 37,643.16 |
| Profit/(Loss) before exceptional items, share of Profit/(Loss) of associates and joint venture and tax | (1,125.49) | 3,374.95 |
| Profit/ (Loss) for the Period | 114.37 | 2,983.28 |
| Basic Earnings per share (EPS) | 0.12 | 3.24 |
Balance Sheet Overview
The financial position of Themis Medicare Limited, both standalone and consolidated, remained relatively stable year over year.Consolidated Balance Sheet (Amount in INR Lakhs)
| Particulars | As at 31/03/2026 | As at 31/03/2025 |
|---|---|---|
| ASSETS | ||
| Total Non-Current Assets | 29,293.10 | 28,416.60 |
| Total Current Assets | 30,497.69 | 30,386.58 |
| TOTAL ASSETS | 59,790.79 | 58,803.18 |
| EQUITY AND LIABILITIES | ||
| Total Equity | 39,858.22 | 40,259.97 |
| Total Non-Current Liabilities | 3,316.61 | 2,930.75 |
| Total Current Liabilities | 16,615.96 | 15,612.46 |
| TOTAL LIABILITIES | 59,790.79 | 58,803.18 |
Cash Flow Analysis
The company’s cash flow statement provides insight into operational movements. For the year ended March 31, 2026, the figures were:| Activity | Amount (INR Lakhs) |
|---|---|
| Cash generated from operations | 313.69 |
| Net cash inflow from operating activities | (326.53) |
| Net cash outflow from investing activities | (254.48) |
| Net cash inflow (outflow) from financing activities | 378.88 |
| Net decrease in cash and cash equivalents | (202.13) |
Cost Auditor Appointment Details
The Board meeting also formalised the appointment of M/s R. Nanabhoy & Co., Cost Accountants (FRN - 000011) as the Cost Auditor for the Financial Year 2026-27. This re-appointment was effective for the period.***
Note: The financial figures above are sourced directly from the audited statements provided by the company.
THEMISMED Stock Price Movement
On Wednesday, shares of Themis Medicare Limited edged higher to close at ₹113.9, gaining 6.14% from the previous day's close. The stock settled at this level, having traded within a range of ₹107.8 to ₹115.89, on a substantial volume of 437,616 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: